Clinical application of blood purification (artificial liver) in treatment of acute liver failure in children

• Published in: Zhonghua er ke za zhi Vol. 52; no. 6; p. 433
• Main Authors: Xu, Xuan, Yu, Bang, Zhu, Bin, Ren, Haili, Feng, Zhichun
• Format: Journal Article
• Language: Chinese
• Published: China 01.06.2014
• Subjects: Adolescent; Bilirubin - blood; Biomarkers - blood; Brain Edema - etiology; Brain Edema - therapy; Child; Child, Preschool; Female; Hemodiafiltration - methods; Heparin - pharmacology; Hepatorenal Syndrome - etiology; Hepatorenal Syndrome - therapy; Humans; Infant; Liver Failure, Acute - blood; Liver Failure, Acute - complications; Liver Failure, Acute - mortality; Liver Failure, Acute - therapy; Liver Function Tests; Male; Plasma Exchange; Prothrombin Time; Survival Rate; Treatment Outcome
• ISSN: 0578-1310

To investigate the clinical application, indication, timing and prognosis of blood purification (artificial liver, BP) in treatment of acute liver failure in children. Artificial liver was used to treat 30 cases of pediatric acute liver failure (PALF), who were hospitalized in pediatric intensive care unit of Bayi Children's Hospital Affiliated to Beijing Military Command General Hospital, during March 2010 to July 2013. Simple plasma exchange (PE) mode was used for PALF without complications, while PE combined with continuous veno-venous hemodiafiltration (CVVHDF) mode was used for PALF with cerebral edema and/or hepatorenal syndrome and/or serious abnormality of electrolyte and acid-base balance. Sixteen cases survived and restored hepatic function, with a survival rate of 53.3%. Single PE therapy could significantly decrease total bilirubin (TBIL) from (293.96 ± 214.52) µmol/L to (155.64 ± 140.97) µmol/L (P = 0.033), increase prothrombin time activity (PTA) from (34.50 ± 18.34) % to (60.50 ± 33.97) % (P =